Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. Ahluwalia MS, Reardon DA, Abad AP, Curry WT, et al. J Clin Oncol 2022 Dec 15:JCO2200996. doi: 10.1200/JCO.22.00996.

Read + Share

Amedeo Smart

Independent Medical Education

Ahluwalia MS, Reardon DA, Abad AP, Curry WT, et al. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol 2022 Dec 15:JCO2200996. doi: 10.1200/JCO.22.00996.
PMID: 36521103